{"product_id":"ibrx-pestle-analysis","title":"(IBRX) ImmunityBio, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis ImmunityBio, Inc. PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces shaping the company and why that matters for strategy and investment. This page shows a real preview of the report so you can judge depth and style; purchase the full version to get the complete, ready-to-use company-specific analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal cancer research ties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio’s collaboration agreements with the National Cancer Institute tie its oncology pipeline to U.S. federal research priorities. The National Cancer Institute’s FY2024 budget was about $7.2 billion, so NIH\/NCI funding trends can shape trial support, site access, and how deeply the partnership runs. If federal cancer funding tightens, ImmunityBio could face slower collaboration momentum and less non-dilutive support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS regulatory pathway reliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc. still leans on the US regulatory path: its late-stage candidates are in Phase II and Phase III, so FDA rules and US trial policy shape both timing and cost. The Company won FDA accelerated approval for ANKTIVA on April 22, 2024, showing how faster paths can speed value. But tighter review or trial rules can still delay readouts and filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health priority diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio’s cancer, SARS-CoV-2, and HIV programs sit in areas that governments track closely: WHO counted 20.0 million new cancer cases in 2022, and AIDS still affected 39.0 million people in 2023. That keeps public funding and policy attention high for vaccines and immunotherapies. Pandemic-readiness plans also favor platforms that can respond to new infectious threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCross-border license exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio, Inc. has cross-border license exposure through deals with Shenzhen Beike Biotechnology Co. Ltd. and Amyris, Inc., so trade policy and U.S.-China tensions can affect access to know-how, IP, and partner support. For biotech, even a single export or cooperation rule change can slow transfers, raise legal risk, and delay development work.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCross-border licenses raise policy risk.\u003c\/li\u003e\n\u003cli\u003eGeopolitics can limit tech access.\u003c\/li\u003e\n\u003cli\u003eRule changes can slow collaboration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFederal health institute partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio, Inc.'s ties with the National Institute on Deafness and Communication Disorders can widen access to federally funded research and speed translational work beyond oncology into immune and vaccine science. NIH support matters because federal grants still fund roughly 80% of U.S. basic research.\u003c\/p\u003e\n\u003cp\u003eThese partnerships can also lift credibility with grant reviewers and public-sector partners, which helps in markets where validation and non-dilutive funding drive adoption. The National Institute on Deafness and Communication Disorders had a FY2025 budget of about $625 million, showing the scale of the research channel.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader research reach beyond cancer\u003c\/li\u003e\n\u003cli\u003eStronger grant and review credibility\u003c\/li\u003e\n\u003cli\u003eAccess to federally funded science networks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunityBio Faces U.S. Policy Risk Despite ANKTIVA Approval\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunityBio’s political risk is tied to U.S. federal research and FDA policy. NIDCD’s FY2025 budget was about $625 million, and the Company’s NCI link keeps it exposed to NIH funding shifts. FDA accelerated approval for ANKTIVA on April 22, 2024 shows policy can speed value, but tighter review or trade rules can still slow trials.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIDCD FY2025 budget\u003c\/td\u003e\n\u003ctd\u003eAbout $625 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eANKTIVA FDA approval\u003c\/td\u003e\n\u003ctd\u003eApril 22, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes how Political, Economic, Social, Technological, Environmental, and Legal factors shape ImmunityBio, Inc.’s strategy, risks, and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise PESTLE snapshot that quickly clarifies ImmunityBio’s external risks and opportunities for faster planning and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of industry reports, clinical data, and regulatory filings to validate ImmunityBio’s market, pricing, and competitive claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo approved product revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio is still a clinical-stage biotech, so it lacks a broad marketed product base like commercial drug makers. That leaves it highly dependent on capital markets and partner funding, especially until product sales scale. In FY2025, the economic risk stays tied to funding access, not stable operating cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase II\/III spend intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhase II\/III bladder, pancreatic, and lung cancer trials are capital-heavy: Phase III oncology studies often enroll hundreds to 1,000+ patients and can cost tens of millions of dollars. ImmunityBio must fund drug supply, site ops, and long follow-up before any sales start. That keeps cash burn high and pushes dilution risk up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnership and licensing funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc. relies on partnerships and licenses to share R\u0026amp;D costs and expand access to assets it would be hard to build alone. These deals can bring upfront cash, milestones, and royalty income, but they also add milestone payment risk and future royalty burdens. The tradeoff is clear: lower net burn now, less margin later.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLarge oncology market exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio, Inc. has large oncology exposure because its pipeline targets bladder, pancreatic, and lung cancers, all high-unmet-need markets. Globally, lung cancer had about 2.48 million new cases in 2022, pancreatic cancer about 510,000, and bladder cancer about 614,000, so even modest win rates can matter. \u003c\/p\u003e\n\u003cp\u003ePositive data in these settings can lift addressable revenue fast, since approved options remain limited and survival gains are often small. That makes each readout commercially sensitive for ImmunityBio, Inc. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBig markets, high need\u003c\/li\u003e\n\u003cli\u003eLung: 2.48M new cases\u003c\/li\u003e\n\u003cli\u003ePancreatic: 510K new cases\u003c\/li\u003e\n\u003cli\u003eBladder: 614K new cases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUS pricing and reimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn the United States, ImmunityBio, Inc. would face tight payer scrutiny because immunotherapy and cell therapy launches often start at list prices above $400,000 per patient, which can trigger prior authorization, step edits, and site-of-care limits. CMS also keeps pressure on reimbursement through Medicare drug negotiation and utilization review, so market access can shape uptake as much as clinical data.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh launch prices raise approval-to-access risk.\u003c\/li\u003e\n\u003cli\u003ePrior auth can slow patient starts.\u003c\/li\u003e\n\u003cli\u003eMedicare controls can cap demand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunityBio’s Growth Hinges on Cash, Trials, and Cancer Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc.’s economic risk in FY2025-FY2026 still hinges on cash access, because it remains clinical-stage and has no broad, steady product revenue. Oncology trials are costly, so dilution and partner funding stay key. Large cancer markets help, but reimbursement can slow uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLung cancer cases\u003c\/td\u003e\n\u003ctd\u003e2.48M (2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePancreatic cancer cases\u003c\/td\u003e\n\u003ctd\u003e510K (2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBladder cancer cases\u003c\/td\u003e\n\u003ctd\u003e614K (2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eImmunityBio, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact ImmunityBio, Inc. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh cancer burden demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc. targets hard-hit cancers such as lung, bladder, and pancreatic disease, and the demand base is huge: the American Cancer Society projects 2,041,910 new U.S. cases and 618,120 deaths in 2025. Globally, GLOBOCAN 2022 estimated 20.0 million new cases and 9.7 million deaths. That scale keeps pressure on payers and doctors to back therapies that can lift survival.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging patient population\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlder adults are becoming a larger share of oncology patients, and age remains one of the strongest risk factors for solid and liquid tumors. The U.S. Census Bureau projects people 65+ will reach 82 million by 2050, up from 58 million in 2022, which widens the need for immune-based cancer care. For ImmunityBio, Inc., this supports a bigger addressable market as cancer incidence rises with age, especially in patients who need less toxic options. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeed in aggressive tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio targets bladder, pancreatic, and lung cancers, where standard care still leaves many patients with short survival. U.S. data show 5-year survival is about 8% for metastatic pancreatic cancer and under 10% for distant lung cancer, so patients and clinicians often seek new immunotherapy options. Bladder cancer also sees frequent relapse, with nearly 83,000 new U.S. cases in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAcceptance of cell therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNK cell and T-cell therapies are harder for patients to accept than standard drugs because they need infusion visits, lab work, and close monitoring for immune side effects. For ImmunityBio, Inc., adoption will depend on clear education and strong trial data, especially since advanced biologics still face more hesitation than pills. Clinical proof matters: the FDA had approved over 30 cell and gene therapies by 2025, but real-world uptake is still uneven.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInfusion care feels more complex\u003c\/li\u003e\n\u003cli\u003eSide effects can raise caution\u003c\/li\u003e\n\u003cli\u003eEducation drives patient trust\u003c\/li\u003e\n\u003cli\u003eClinical evidence supports adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInfectious disease awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio, Inc. benefits from strong infectious-disease awareness because COVID-19 made immune protection a mainstream issue, with over 13 billion vaccine doses given worldwide by 2024. The Company’s SARS-CoV-2 and HIV programs fit that shift in public focus. HIV still affects about 39 million people globally, so advocacy and long-term demand stay high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSARS-CoV-2 stays a visible immune-health market.\u003c\/li\u003e\n\u003cli\u003eHIV keeps strong public and policy attention.\u003c\/li\u003e\n\u003cli\u003eCOVID-19 raised vaccine literacy worldwide.\u003c\/li\u003e\n\u003cli\u003eLarge patient need supports pipeline relevance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunityBio Gains as Cancer Cases and Aging Populations Surge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc. benefits from rising cancer burden and an aging patient base: ACS projects 2,041,910 new U.S. cancer cases in 2025, while the U.S. Census says people 65+ will reach 82 million by 2050. Patients with metastatic pancreatic cancer still face about 8% 5-year survival, so demand for new immunotherapies stays high. Adoption depends on trust, education, and clear trial data.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer burden\u003c\/td\u003e\n\u003ctd\u003e2,041,910 U.S. cases in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAging\u003c\/td\u003e\n\u003ctd\u003e82 million age 65+ by 2050\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeed\u003c\/td\u003e\n\u003ctd\u003e~8% 5-year survival in metastatic pancreatic cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-platform immunotherapy stack\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio’s multi-platform stack spans antibody-cytokine fusion proteins, synthetic immunomodulators, vaccines, and cell therapy, so one R\u0026amp;D engine can feed several product candidates. That matters because the company now has 1 FDA-approved asset, ANKTIVA, and a broader pipeline to reuse its immune-system playbook. This mix can spread risk and speed follow-on programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNK and T-cell engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio’s NK and T-cell engineering stays central to its tumor and pathogen targeting strategy, with ANKTIVA gaining U.S. FDA approval in April 2024 and the company pushing broader cellular programs in 2025. These platforms depend on tight translational science and precise biologic control, because even small shifts in cell potency or persistence can change outcomes. The upside is real, but so are the execution risks tied to manufacturing scale and clinical proof.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLate-stage clinical complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc. still faces late-stage clinical complexity because Phase II and Phase III studies must prove clear endpoints, biomarker value, and batch-to-batch manufacturing consistency. In late-stage oncology, a small shift in response or safety can decide approval, so execution matters as much as the signal. That makes tech quality and CMC control a direct value driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiologic manufacturing scale-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiologic manufacturing scale-up is a major risk for ImmunityBio, Inc. because cell therapies and fusion proteins are far harder to make than simple molecules. The real bottlenecks are scale-up, quality control, and batch-to-batch consistency, and any failure can push back trials and raise cash burn.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHard to scale cleanly\u003c\/li\u003e\n\u003cli\u003eQC can delay release\u003c\/li\u003e\n\u003cli\u003eBatch failures raise costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePlatform reuse across diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio, Inc. is using one immune platform across cancer and infectious disease, which can recycle core science across multiple indications. That can lower development duplication, but it also makes assay, formulation, and delivery systems more important because the same biology must work in very different settings. One platform, two disease classes, higher reuse and higher technical demands.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShared platform can speed new indications\u003c\/li\u003e\n\u003cli\u003eCross-disease reuse may cut R\u0026amp;D duplication\u003c\/li\u003e\n\u003cli\u003eFlexible assays and delivery are critical\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunityBio’s Multi-Platform Edge Faces Manufacturing Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunityBio’s tech edge is its multi-platform immune stack, with ANKTIVA approved by the U.S. FDA in April 2024 and a pipeline built to reuse the same biology across cancer and infection. That lowers duplication, but it also makes assay, delivery, and batch control core risks.\u003c\/p\u003e\n\u003cp\u003eCell therapy and fusion-protein manufacturing stay the main bottlenecks, since potency and consistency can shift trial outcomes fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA-approved asset\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eANKTIVA approval\u003c\/td\u003e\n\u003ctd\u003eApr 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore platform types\u003c\/td\u003e\n\u003ctd\u003e4+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA trial compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio’s pipeline still sits in Phase II and Phase III, so FDA rules on patient safety, adverse-event reporting, and protocol amendments remain strict. The company already has one FDA-approved product, ANKTIVA, but late-stage trial slips can still delay readouts or force redesigns. Any noncompliance can pause enrollment, extend timelines, and raise cash burn in a program-heavy business.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicense-heavy IP structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc. operates under a license-heavy IP model with at least five named counterparties: CytRx, EnGeneIC, GlobeImmune, IDRI and Viracta. That means one product can sit across multiple royalty, milestone and field-use terms, which raises legal overlap risk. In 2025\/2026, this kind of structure can slow dealmaking and make freedom-to-operate checks more costly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaboration contract obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc. has active collaborations with the NCI and NIDCD, so its legal risk includes milestone, publication, and data-sharing duties tied to each agreement. Two federal partnerships can speed development, but missed deliverables or contract disputes can still delay programs and reset timelines. In research deals, even one obligation slip can slow access to shared data and trial support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical data privacy rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio, Inc.’s cancer and infectious-disease trials must protect patient records, consent files, and safety data under HIPAA and the Common Rule. That raises compliance cost and slows study ops, because every data handoff, adverse-event log, and re-consent step must be audit-ready. US civil HIPAA penalties can reach about $2.1 million per violation category in 2025.\u003c\/p\u003e\n\u003cp\u003eFor a trial-heavy Company Name, privacy lapses can trigger delays, site audits, and loss of trust with IRBs and investigators. If any study uses 25+ sites, data-sharing controls get harder fast, so secure systems and tight access logs matter more than ever.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHIPAA and Common Rule drive heavy oversight\u003c\/li\u003e\n\u003cli\u003eConsent and safety records need strict control\u003c\/li\u003e\n\u003cli\u003ePrivacy breaches can stall trials and raise costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProduct liability exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio, Inc.’s immunotherapy and cell therapy products can trigger serious adverse events, so any approved product would need tight labeling and ongoing pharmacovigilance. In late-stage biotech, that means legal exposure can rise fast if safety signals appear after launch. Strong recall, reporting, and indemnity controls are not optional.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSevere adverse events can drive claims.\u003c\/li\u003e\n\u003cli\u003eLabeling must match real safety data.\u003c\/li\u003e\n\u003cli\u003ePost-market monitoring stays critical.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA, IP, and HIPAA risks can delay ImmunityBio and drive up costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc. faces strict FDA and trial-law oversight in 2025\/2026, so any adverse-event, protocol, or labeling lapse can delay programs and raise cash burn. \u003c\/p\u003e\n\u003cp\u003eIts license-heavy IP setup and federal research deals also add contract, royalty, and data-sharing risk. \u003c\/p\u003e\n\u003cp\u003eHIPAA and the Common Rule keep patient data controls tight; 2025 HIPAA civil penalties can reach $2,134,831 per violation category.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eHIPAA civil penalty cap\u003c\/td\u003e\n\u003ctd\u003e$2,134,831\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioprocess waste streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiotech labs generate biohazardous and chemical waste, so ImmunityBio, Inc. must segregate, treat, and document disposal under EPA and state rules. Waste handling adds direct cost to R\u0026amp;D and clinical operations, especially for sharps, solvents, and contaminated single-use plastics. Tighter standards also raise audit risk and can slow lab throughput if pickup or manifests slip.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCold-chain logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc.’s cell therapies and biologics rely on tight cold-chain control, often 2°C–8°C or frozen storage, so transport and warehousing add energy use and complexity. WHO says about 50% of vaccines are wasted worldwide each year, with temperature breaks a major cause, showing how a single excursion can hurt product quality and trial integrity. This raises cost, risk, and compliance pressure across the supply chain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy-intensive production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvanced biologics manufacturing uses more energy than small-molecule production because cell processing, purification, and quality testing all add power and utility load. For ImmunityBio, Inc., that makes efficiency a real cost issue as scale rises, since energy use and waste handling can climb fast in late-stage and commercial production. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCalifornia operating risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio, Inc. is based in San Diego, California, so state-level wildfire, drought, and power outage risk can hit operations directly. California had 7,127 wildfires in 2024, and utility shutoffs or grid stress can disrupt labs, offices, staffing, and cold-chain supply flow. That makes site resilience and backup power more than a cost issue; it is an operating need.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWildfires can block staff access.\u003c\/li\u003e\n\u003cli\u003eDrought can strain local utilities.\u003c\/li\u003e\n\u003cli\u003eOutages can interrupt supply continuity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSustainable sourcing pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSustainable sourcing is a real risk for ImmunityBio, Inc. because biotech depends on specialized reagents, single-use consumables and temperature-controlled shipping, so supplier emissions can sit deep in Scope 3, which often makes up more than 70% of a life science company’s footprint. Investors and partners now expect lower-carbon supply chains; CDP says supply-chain emissions can be 11x higher than direct emissions, so vendor choice affects both cost and reputation. That makes supplier audits, greener freight and backup sourcing part of procurement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScope 3 often exceeds 70%\u003c\/li\u003e\n\u003cli\u003eSupplier choice affects reputation\u003c\/li\u003e\n\u003cli\u003eGreener freight reduces risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunityBio Faces Rising Waste, Power, and Wildfire Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc. faces higher environmental cost from biohazard waste, cold-chain power use, and California wildfire and outage risk. WHO says about 50% of vaccines are wasted worldwide each year, showing how temperature breaks can damage biologics. California had 7,127 wildfires in 2024, raising site-resilience needs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWildfires\u003c\/td\u003e\n\u003ctd\u003e7,127\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccine waste\u003c\/td\u003e\n\u003ctd\u003e50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234591351049,"sku":"ibrx-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ibrx-pestle-analysis.webp?v=1785721547","url":"https:\/\/dcfanalyst.com\/products\/ibrx-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}